The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
inalimarev
A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine recombinant vaccinia-CEA-MUC1-TRICOM vaccine rVaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine vaccinia-CEA-MUC-1-TRICOM vaccine | |
| |||
| US brand name: | | PANVAC-V | |
| |||
| Abbreviation: | | vCEA-MUC-1-TRI | |
| |||
